Literature DB >> 16959612

C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells.

Roger R Gomis1, Claudio Alarcón, Cristina Nadal, Catherine Van Poznak, Joan Massagué.   

Abstract

Breast cancers may evade the growth-inhibitory action of TGFbeta by accumulating defects of unknown nature that selectively eliminate cytostatic gene responses. We found the transcription factor C/EBPbeta to be essential for TGFbeta induction of the cell cycle inhibitor p15INK4b by a FoxO-Smad complex and repression of c-MYC by an E2F4/5-Smad complex in human epithelial cells. These cytostatic responses are selectively missing in metastatic breast cancer cells from half of the patients that we tested. The basis for this loss was traced to an excess of the C/EBPbeta inhibitory isoform LIP. We suggest that C/EBPbeta plays a key role in the coordination of TGFbeta cytostatic gene responses, and its malfunction may trigger evasion of these responses in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959612     DOI: 10.1016/j.ccr.2006.07.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  127 in total

Review 1.  New insights for FOXO and cell-fate decision in HIV infection and HIV associated neurocognitive disorder.

Authors:  Min Cui; Yunlong Huang; Yong Zhao; Jialin Zheng
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

2.  TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma.

Authors:  Naoki Oshimori; Daniel Oristian; Elaine Fuchs
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

3.  Transcriptional regulation of O-GlcNAc homeostasis is disrupted in pancreatic cancer.

Authors:  Kevin Qian; Simeng Wang; Minnie Fu; Jinfeng Zhou; Jay Prakash Singh; Min-Dian Li; Yunfan Yang; Kaisi Zhang; Jing Wu; Yongzhan Nie; Hai-Bin Ruan; Xiaoyong Yang
Journal:  J Biol Chem       Date:  2018-07-23       Impact factor: 5.157

4.  MUC1-C oncoprotein activates ERK→C/EBPβ signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells.

Authors:  Maroof Alam; Rehan Ahmad; Hasan Rajabi; Akriti Kharbanda; Donald Kufe
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

5.  The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway.

Authors:  Barbara Marinari; Francesca Moretti; Elisabetta Botti; Maria Laura Giustizieri; Pascal Descargues; Alessandro Giunta; Carmine Stolfi; Costanza Ballaro; Marina Papoutsaki; Stefano Alemà; Giovanni Monteleone; Sergio Chimenti; Michael Karin; Antonio Costanzo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

6.  EGFR and C/EBP-β oncogenic signaling is bidirectional in human glioma and varies with the C/EBP-β isoform.

Authors:  Ligia Selagea; Alok Mishra; Monika Anand; James Ross; Carol Tucker-Burden; Jun Kong; Daniel J Brat
Journal:  FASEB J       Date:  2016-08-29       Impact factor: 5.191

7.  Foxg1 promotes olfactory neurogenesis by antagonizing Gdf11.

Authors:  Shimako Kawauchi; Joon Kim; Rosaysela Santos; Hsiao-Huei Wu; Arthur D Lander; Anne L Calof
Journal:  Development       Date:  2009-03-18       Impact factor: 6.868

Review 8.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

9.  NFkappaB p50-CCAAT/enhancer-binding protein beta (C/EBPbeta)-mediated transcriptional repression of microRNA let-7i following microbial infection.

Authors:  Steven P O'Hara; Patrick L Splinter; Gabriella B Gajdos; Christy E Trussoni; Martin E Fernandez-Zapico; Xian-Ming Chen; Nicholas F LaRusso
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

10.  CCAAT/enhancer binding protein beta regulates stem cell activity and specifies luminal cell fate in the mammary gland.

Authors:  Heather L LaMarca; Adriana P Visbal; Chad J Creighton; Hao Liu; Yiqun Zhang; Fariba Behbod; Jeffrey M Rosen
Journal:  Stem Cells       Date:  2010-03-31       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.